NCT06441630RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
Source: ClinicalTrials.gov · Last updated 4 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (estimated)
- First submitted
- 29 May 2024
- Start date
- 31 Jul 2024
- Primary completion date
- Sept 2025
- Lead sponsor
- Addpharma Inc.
- Diseases
- High blood pressure
- NCT number
- NCT06441630
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 251
- From 31 Jul 2024 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with Secondary Hypertension
Other
- Other exclusions applied
Who the study is looking for
- Signed informed consent
- Patients with Essential Hypertension
- Other inclusions applied
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gangnam CHA Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.